Chai Discovery
AI-native biotech building foundation models that predict and reprogram biochemical interactions for accelerated drug discovery — Chai-1 for structural prediction and Chai-2 for zero-shot generative antibody design, with a December 2025 $130M Series B at a $1.3B valuation and a January 2026 multi-year licensing partnership with Eli Lilly.
The Business
Chai Discovery is an AI-native biotech company building foundation models that predict and reprogram biochemical interactions for accelerated drug discovery. The product line covers two principal model families: Chai-1 for structural prediction (the protein-and-complex structure-prediction model that sits in the same lineage as AlphaFold and ESM) and Chai-2 for zero-shot generative antibody design (the company’s published claim is double-digit experimental success rates in de novo antibody design, a 100x improvement over prior computational methods). The company was founded in 2024 in San Francisco by Joshua Meier (CEO, ex-Meta FAIR ESM research), Jack Dent (CTO) and Jacques Boitreaud and has raised approximately $230M of external capital through the December 2025 $130M Series B at a $1.3B valuation, co-led by General Catalyst and Oak HC/FT with continued participation from Menlo Ventures (Series A lead), OpenAI, Dimension, Thrive Capital, Neo, Yosemite, Lachy Groom and SV Angel and new investors Glade Brook and Emerson Collective.
Customers and Distribution
Chai Discovery’s commercial development model is partnership-led licensing with pharma counterparties rather than subscription SaaS. The principal disclosed partnership at the Series B point is the January 2026 multi-year licensing deal with Eli Lilly, under which Eli Lilly pays an undisclosed annual access fee for deploying Chai’s models across its therapeutic portfolio. Additional pharma partnerships have not been publicly disclosed at comparable licensing-fee scale. The platform serves the company’s own research-pipeline workflows and the partner pharma counterparties’ molecular-design and antibody-discovery teams; the commercial development model is structurally similar to Isomorphic Labs at Alphabet, EvolutionaryScale and Generate Biomedicines — the AI-bio partnership-led commercial-development pattern. Customer concentration on the single Eli Lilly anchor partnership is the load-bearing commercial-development risk at this stage; the watched event is whether subsequent pharma partnerships at comparable scale anchor in 2026.
Model Strategy
Chai Discovery is a Frontier-first play under the IM Framework eight-trajectories taxonomy as it applies to AI-native drug discovery: the strategic bet is that frontier capability in foundation models for molecular design — the structural-prediction model lineage from AlphaFold and ESM, combined with the zero-shot generative-design pivot in Chai-2 — beats both legacy in-silico drug-discovery tools and incumbent pharma R&D pipelines at the de novo antibody and small-molecule design surface. The model strategy is unusual in the cohort because Chai operates first-party research foundation models (Chai-1, Chai-2) and a wet-lab integration that anchors the experimental-validation pipeline; the company is not a model-routing play and does not depend on third-party foundation-model providers in the same way as a horizontal AI-application company. The D4a supplier-diversity sub-rubric was held at 6 in the v1.6 evidence pass on that basis: Chai is research-foundation-model first, with compute supplied by hyperscaler partners and the broader research community (the ESM and AlphaFold lineages) providing the underlying scientific scaffolding. The secondary strategic axis is the regulatory pathway for AI-designed therapeutics, which Chai is positioned to help anchor with named pharma partnership references.
At A Glance
The Numbers
Active pharma partnerships
Headcount (FTE)
Funding to date
Leadership Team
Chai Discovery is privately held and does not separately disclose a full C-suite layer. The founder trio (Meier CEO, Dent CTO, Boitreaud) remains in place across the Series A and Series B cycles. Senior recruiting through 2025 was concentrated on the AI-research and wet-lab integration teams alongside the GTM build-out to support the Eli Lilly partnership and prospective additional pharma counterparties. No CRO, CFO or COO has been separately publicly disclosed; the company is at the stage where partnership-led commercial development matters more than enterprise-software-style GTM hiring.
IM Framework Scoring
IM’s structured assessment of Chai Discovery’s competitive position. The summary below is the headline; expand “Show the full analyst-grade analysis” near the bottom for the per-dimension reasoning and evidence. Methodology →
Funding History
| Date | Round | Raised | Post-money | Lead investor(s) |
|---|---|---|---|---|
| Dec 2025 | Series B | $130M | $1.3B | General Catalyst & Oak HC/FT (co-led; with Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite, Lachy Groom, SV Angel, Glade Brook, Emerson Collective) |
| Aug 2025 | Series A | $70M | — | Menlo Ventures (via Anthology Fund) (with Yosemite, DST Global Partners, SV Angel, Avenir, DCVC, Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, Fred Ehrsam) |
| 2024 | Seed | ~$30M | — | Thrive Capital (with OpenAI, Dimension, Neo, Lachy Groom) |
Cumulative external capital approximately $230M through the December 2025 $130M Series B at a $1.3B valuation, co-led by General Catalyst and Oak HC/FT with continued participation from Menlo Ventures (Series A lead), OpenAI, Dimension, Thrive Capital, Neo, Yosemite, Lachy Groom and SV Angel and new investors Glade Brook and Emerson Collective. The Series A in August 2025 was led by Menlo Ventures through the Anthology Fund (Menlo’s joint partnership with Anthropic) at $70M. Round-by-round figures from Chai Discovery’s own Series B announcement and named-press coverage at TechCrunch.
Competitive Landscape
Chai Discovery’s competitive set sits in three concentric rings: the symmetric AI-native foundation-model drug-discovery startups (Isomorphic Labs from DeepMind, EvolutionaryScale from Meta FAIR) that share the foundation-model research lineage, the well-funded AI-bio platforms with strong wet-lab integration (Generate Biomedicines, Insilico Medicine, Recursion Pharmaceuticals) that flank from different methodological anchors, and the broader pharma-internal AI-drug-discovery investments at the named pharma counterparties (Eli Lilly’s internal AI capabilities, the Novartis-Microsoft partnership, the Recursion-Roche partnership) that determine whether AI-native startups can sustain access to the partnership channel. The defining structural risk is that AI-bio is a long-cycle commercial development category where wet-lab validation and clinical translation matter more than software ARR signals.
| Competitor | Positioning | Distribution edge | Threat profile |
|---|---|---|---|
| Isomorphic Labs (Alphabet (DeepMind spin-out)) |
Alphabet’s drug-discovery company spun out of DeepMind — building on the AlphaFold protein-structure-prediction heritage with foundation-model approaches to drug design. The most-cited AI-bio competitor and structurally symmetric play on the foundation-model approach to drug discovery. | Partnership-led with named pharma deals at Eli Lilly and Novartis as the lead references; Alphabet capital backing as the strategic anchor. | High — structurally symmetric play with the deepest research heritage in the cohort (AlphaFold credibility) and the strongest pharma partnership reference set; the principal head-to-head where AI-native drug-discovery procurement sits. |
| EvolutionaryScale | AI-bio startup spun out of Meta FAIR”s ESM team (the same protein-language-model research heritage as Chai) with a foundation-model approach to protein design. Direct overlap with Chai on the underlying research lineage. | Partnership-led with named pharma deals; strategic backing from Amazon, Nvidia and Lux Capital per the company”s funding disclosures. | High — same research lineage as Chai and structurally symmetric on the foundation-model approach; the principal flanking competitor for the same talent and partnership opportunities. |
| Generate Biomedicines | AI-native therapeutics company — Flagship Pioneering portfolio company — building generative-AI platforms for biologics design across antibodies, peptides and protein engineering. Strong wet-lab integration as the differentiator. | Partnership-led with named pharma deals at Amgen and Novartis; Flagship Pioneering platform support as the structural anchor. | Medium-High — well-funded competitor with deeper wet-lab integration than Chai today; less foundation-model-research-first than Chai or EvolutionaryScale. |
| Insilico Medicine | Established AI-drug-discovery company with end-to-end pipeline from target identification through clinical-stage assets; the most mature commercial AI-bio competitor with assets in clinical trials. | Partnership-led with named pharma deals at Sanofi and others; Hong Kong / US dual-listing trajectory; clinical-stage asset references. | Medium — further along the commercial development path than Chai but less concentrated on the foundation-model design surface where Chai positions; complementary in many respects. |
| Recursion Pharmaceuticals | Publicly listed AI-drug-discovery company (NASDAQ: RXRX) with the BioHive supercomputer and a phenotypic-image-based AI pipeline. Adjacent on the AI-bio surface with a different methodological lean than foundation-model design. | Partnership-led with named pharma deals at Bayer and Roche; public-market funding via the NASDAQ listing. | Medium — adjacent rather than directly competitive on the foundation-model design surface; competes for the same pharma partnership opportunities. |
Pricing benchmark: AI-bio commercial development frames are partnership-led licensing deals with annual access fees and milestone-and-royalty structures, not subscription ARR. The Eli Lilly partnership disclosed an undisclosed annual access fee for licensing Chai-2 models across the therapeutic portfolio. Isomorphic Labs disclosed similar partnership economics at Eli Lilly and Novartis. EvolutionaryScale and Generate Biomedicines partnership economics are similar in shape. The competitive frame is therefore the depth and durability of the pharma partnership reference set plus the underlying technical capability of the foundation-model platform — not headline per-seat or per-token price.
Potential Risks
The case for Chai Discovery at IM Framework 6.72 rests on the foundation-model research lineage (ESM heritage from Meta FAIR via co-founder Joshua Meier), the Chai-2 reported zero-shot antibody-design experimental success rates (double-digit, 100x prior computational methods per the company”s published claim), the December 2025 $130M Series B at $1.3B valuation closed inside 16 months of the Series A, the OpenAI strategic backing across both rounds, and the January 2026 Eli Lilly multi-year licensing partnership at an undisclosed annual access fee. The case against splits into five risks of differing magnitude — with very early commercial traction the most structural, FDA regulatory-pathway uncertainty on AI-designed therapeutics the most policy-driven, and the competitive density across the AI-bio cohort the most active.
Very early commercial traction — one disclosed pharma partnership at the licensing-fee scale
Chai Discovery’s commercial book at the Series B disclosure point rests on the January 2026 Eli Lilly multi-year licensing partnership with an undisclosed annual access fee (specific structure not publicly disclosed in primary sources). No second pharma partnership at comparable scale has been publicly disclosed and no Chai-designed candidate has reached IND-enabling studies. The D4d capital position sub-rubric was held at 9 in the v1.6 evidence pass on the strength of the $230M cumulative capital; the D4a customer-mix sub-rubric reflects the concentration on a single anchor partnership. The bull case is that the Eli Lilly partnership is the reference deal that anchors subsequent pharma counterparties; the bear case is that AI-bio is a long-cycle commercial development category and the partnership-led commercial book takes years to scale.
Regulatory-load uncertainty on AI-designed therapeutics
The FDA’s evolving stance on computational biology and AI-designed therapeutics is a load-bearing uncertainty on the commercial development path. The FDA released draft guidance on AI in drug development through 2024-2025 but the specific regulatory pathway for AI-designed biologics (including the documentation, model-transparency and clinical-validation requirements) remains in active formation. The D4c regulatory-exposure sub-rubric was held at 6 in the v1.6 evidence pass on that basis. The bull case is that early-mover positioning with the FDA helps anchor the regulatory pathway; the bear case is that any sustained regulatory friction extends the commercial development timeline and compresses the present value of partnership-led licensing revenue.
Competitive density across the AI-bio cohort
Isomorphic Labs (Alphabet), EvolutionaryScale (Meta FAIR lineage), Generate Biomedicines (Flagship Pioneering), Insilico Medicine and Recursion Pharmaceuticals are all well-funded competitors at the AI-bio surface with overlapping pharma partnership ambitions. The D4e key-person dependency sub-rubric was held at 5 in the v1.6 evidence pass on the founder-trio concentration; the broader competitive density is the principal structural risk on the disruption composite. The bull case is that Chai-2’s reported zero-shot antibody-design experimental success rates differentiate the platform on technical capability; the bear case is that the named competitor set is funded and credentialed at comparable scale and that pharma counterparties will multi-source AI-bio partnerships rather than consolidate spend on any single platform.
Key-person dependency on the founder trio
Joshua Meier (CEO), Jack Dent (CTO) and Jacques Boitreaud are the founder trio and the principal public voices on the platform, the underlying research and the Series B narrative. The D4e key-person dependency sub-rubric was held at 5 in the v1.6 evidence pass on that evidence. No CRO, CFO or COO has been separately publicly disclosed. The bull case is that founder continuity at this scale anchors the technical and partnership reputations that drive pharma-counterparty engagement; the bear case is that scaling beyond the Eli Lilly anchor partnership requires a senior commercial-development bench that has not yet been built.
Mark-up risk between Series A and Series B
Chai Discovery closed the Series A in August 2025 at $70M with $100M cumulative funding and the Series B four months later in December 2025 at $130M at a $1.3B valuation. The compressed timeline reflects the speed of the AI-bio investment cycle and the strength of the Chai-2 disclosure but creates a mark-up risk at any subsequent round if the Eli Lilly partnership economics do not scale through 2026. The D4d capital position sub-rubric was held at 9 in the v1.6 evidence pass on the strength of the $230M cumulative capital; the watched event is whether subsequent rounds confirm the trajectory at higher marks or compress the implied path.
Recent IM Coverage
- Healthcare AI — Sector Page Jun 2026.
- AI Tracker Methodology — IM Framework v1.6 May 2026.
Show recent press coverage of Chai Discovery
- Dec 2025 — Chai Discovery announces $130 million Series B to transform molecular discovery.
- Dec 2025 — OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation.
- Aug 2025 — Chai Discovery announces $70 million Series A to transform molecular design.
- Aug 2025 — AI molecular design startup Chai Discovery secures $70M Series A.
Curated feed of named-source coverage — Chai Discovery’s own BusinessWire announcements for the Series A and Series B rounds plus named-press coverage at TechCrunch and Built In San Francisco. The Series A and Series B BusinessWire announcements are the canonical references for round-size, valuation and investor-syndicate figures cited on this page. Excludes paywalled article bodies of The Information, WSJ, FT, Bloomberg and STAT News and PR-wire reposts of the same release.
Show the source register for the figures on this page
IM operates a primary-source-where-possible discipline. The figures above come from:
- Revenue: Chai Discovery is private and at the partnership-led commercial development stage rather than the SaaS-ARR stage. The January 2026 TechCrunch coverage of the Series B and subsequent reporting on the Eli Lilly partnership reference an undisclosed annual access fee for the multi-year licensing of Chai-2 models. We label this “partnership licensing fee” rather than ARR and decline-to-publish a consolidated revenue figure pending additional disclosed partnerships at comparable scale.
- Usage — pharma partnerships and platform signal: Chai Discovery’s December 2025 Series B announcement and the company’s own website disclose Chai-1 for structural prediction and Chai-2 for zero-shot generative antibody design with reportedly double-digit experimental success rates (100x improvement over prior computational methods per the company’s published claim). The principal disclosed pharma partnership at the Series B point is the January 2026 Eli Lilly multi-year licensing deal.
- Headcount (basis-disclosure note): Chai Discovery is private and does not separately disclose precise headcount. Public references through the Series B cycle place the company in the low-tens to low-hundreds range with continued hiring across the AI-research and wet-lab integration teams. We reference the Chai Discovery careers page as the canonical entry point and decline-to-publish a precise headcount pending a primary disclosure.
- Funding to date: Cumulative external capital approximately $230M through the December 2025 $130M Series B at $1.3B post-money, co-led by General Catalyst and Oak HC/FT with Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite, Lachy Groom, SV Angel and new investors Glade Brook and Emerson Collective participating. Prior rounds: August 2025 $70M Series A led by Menlo Ventures through the Anthology Fund; 2024 seed round at approximately $30M led by Thrive Capital with OpenAI, Dimension, Neo and Lachy Groom.
Methodology & Disclaimer
For metric definitions, source-tier hierarchy, and decline-to-publish rules, see the tracker methodology. Confidence dots (• green / • amber / • red) follow the same convention as the AI Tracker.
Spotted a figure you believe is wrong? Send corrections to info@informationmatters.net.
Information Matters Framework scores are the considered opinion of the IM team — human and AI — applied to publicly-available evidence under a disclosed methodology. They are not statements of fact about the companies scored and they are not investment advice.
